breast cancer - HR positive | ||
la/mBC - HR-positive - 1st line (L1) | la/mBC - HR-positive - 2nd line (L2) | |
IGF-1R inhibitors | ||
dalotuzumab plus ridaforolimus plus exemestane | MK-8669-064 | |
ganitumab plus endocrine therapy | QUILT-2.015 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -